Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)
Clinical trial NCT04278222 · UNKNOWN
Trial details
- NCT number
- NCT04278222
- Sponsor
- Shanghai Changzheng Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-02-10
- Primary completion
- 2024-10-31
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.